A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas
Status:
Completed
Trial end date:
2015-01-31
Target enrollment:
Participant gender:
Summary
To evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a potential
rituximab biosimilar) in patients with CD20-positive B-cell lymphomas.